Quick Answer
Zymeworks Inc. reported Cash and Equivalents of $41.16 million for fiscal year 2025.
Zymeworks Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $41.16M | -37.7% |
| 2024 | $66.10M | -58.0% |
| 2023 | $157.56M | -60.7% |
| 2022 | $400.91M | +98.6% |
| 2021 | $201.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $64.83M | -47.0% | -34.0% |
| June 30, 2025 | $98.25M | +38.5% | +28.9% |
| March 31, 2025 | $76.20M | -33.6% | +15.3% |
| December 31, 2024 | $66.10M | -58.0% | -46.0% |
| September 30, 2024 | $122.36M | +29.7% | +72.4% |
| June 30, 2024 | $70.96M | -50.1% | -38.2% |
| March 31, 2024 | $114.81M | -36.8% | -27.1% |
| December 31, 2023 | $157.56M | -60.7% | +67.0% |
- Zymeworks Inc. showed a decrease of -37.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Zymeworks Inc.’s cash and equivalents has declined by 79.6% (from $201.87 million to $41.16 million).
- The most recent figure is from Zymeworks Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: